Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) has provided an announcement.
Neurizon Therapeutics has reported a change in the holdings of director Dr Michael Thurn, who maintains both direct and indirect interests in the company through family accounts and personal holdings of shares, options and performance rights. The notice confirms the lapse or disposal of 1,000,000 unlisted options expiring on 19 January 2026 at $0.175, with no consideration received, leaving Dr Thurn’s remaining interests concentrated in fully paid ordinary shares, listed options, longer-dated unlisted options and performance rights, and signalling a modest simplification of his short‑dated derivative exposure without altering his substantial alignment with shareholders.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company focused on developing therapeutic products in the pharmaceutical and life sciences sector, with its shares and options listed on the Australian Securities Exchange.
Average Trading Volume: 504,929
Technical Sentiment Signal: Sell
Current Market Cap: A$68.84M
For detailed information about NUZ stock, go to TipRanks’ Stock Analysis page.